Organon & Co. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
Organon & Co. (OGN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 0 shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-31.
Financial Statements › Shareholders' Equity
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-07-31
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 0.00 shares.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 0.00 shares, a 100.00% decline year-over-year.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 0.00 shares.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 0.00 shares.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 2.59M shares, a 72.12% increase from fiscal 2024.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 1.50M shares, a 99.87% decline from fiscal 2023.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 1.12B shares, a 102.16% increase from fiscal 2022.
- Organon & Co. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2022 was 556.00M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 4 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 7 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-31 | 0.00 shares 10-Q · filed 2026-07-31 | 0.00 shares derived: sum of 3 quarters · filed 2026-07-31 | 0.00 shares derived: sum of 4 quarters · filed 2026-07-31 | |||
| 2026-03-31 | 0.00 shares 10-Q · filed 2026-05-04 | 0.00 shares derived: sum of 2 quarters · filed 2026-05-04 | 0.00 shares derived: sum of 3 quarters · filed 2026-05-04 | 0.00 shares derived: sum of 4 quarters · filed 2026-05-04 | |||
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-24 | 0.00 shares derived: sum of 2 quarters · filed 2026-02-24 | 0.00 shares derived: sum of 3 quarters · filed 2026-02-24 | 2.59M shares 10-K · filed 2026-02-24 | |||
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | 0.00 shares derived: sum of 2 quarters · filed 2025-11-10 | 2.59M shares 10-Q · filed 2025-11-10 | -1.50B shares derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 2.59M shares 10-Q · filed 2025-08-06 | -1.50B shares derived: sum of 3 quarters · filed 2025-11-10 | -1.50B shares derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2025-03-31 | 2.59M shares 10-Q · filed 2025-05-02 | -1.50B shares derived: sum of 2 quarters · filed 2025-11-10 | -1.50B shares derived: sum of 3 quarters · filed 2025-11-10 | -1.50B shares derived: sum of 4 quarters · filed 2025-11-10 | |||
| 2024-12-31 | -1.50B shares derived: 10-K/A 12 month − 10-Q 9 month · filed 2025-11-10 | -1.50B shares derived: sum of 2 quarters · filed 2025-11-10 | -1.50B shares derived: sum of 3 quarters · filed 2025-11-10 | 1.50M shares 10-K/A · filed 2025-11-10 | 1.50B shares 10-K · filed 2025-02-28 | ||
| 2024-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-01 | 0.00 shares derived: sum of 2 quarters · filed 2024-11-01 | 1.50B shares 10-Q · filed 2024-11-01 | 1.50B shares derived: sum of 4 quarters · filed 2024-11-01 | |||
| 2024-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | 1.50B shares 10-Q · filed 2024-08-07 | 1.50B shares derived: sum of 3 quarters · filed 2024-08-07 | 1.50B shares derived: sum of 4 quarters · filed 2024-08-07 | |||
| 2024-03-31 | 1.50B shares 10-Q · filed 2024-05-03 | 1.50B shares derived: sum of 2 quarters · filed 2024-05-03 | 1.50B shares derived: sum of 3 quarters · filed 2024-05-03 | 1.50B shares derived: sum of 4 quarters · filed 2024-05-03 | |||
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | 0.00 shares derived: sum of 2 quarters · filed 2024-02-26 | 0.00 shares derived: sum of 3 quarters · filed 2024-02-26 | 1.12B shares 10-K · filed 2024-02-26 | |||
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-03 | 0.00 shares derived: sum of 2 quarters · filed 2023-11-03 | 1.12B shares 10-Q · filed 2023-11-03 | 1.12B shares derived: sum of 4 quarters · filed 2023-11-03 | |||
| 2023-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | 1.12B shares 10-Q · filed 2023-08-09 | 1.12B shares derived: sum of 3 quarters · filed 2023-08-09 | 1.12B shares derived: sum of 4 quarters · filed 2023-08-09 | |||
| 2023-03-31 | 1.12B shares 10-Q · filed 2023-05-05 | 1.12B shares derived: sum of 2 quarters · filed 2023-05-05 | 1.12B shares derived: sum of 3 quarters · filed 2023-05-05 | 1.68B shares derived: sum of 4 quarters · filed 2023-05-05 | |||
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 0.00 shares derived: sum of 2 quarters · filed 2023-02-27 | 555.44M shares derived: sum of 3 quarters · filed 2023-02-27 | 556.00M shares 10-K · filed 2023-02-27 | |||
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | 555.44M shares derived: sum of 2 quarters · filed 2022-11-04 | 556.00M shares 10-Q · filed 2022-11-04 | ||||
| 2022-06-30 | 555.44M shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-05 | 556.00M shares 10-Q · filed 2022-08-05 | |||||
| 2022-03-31 | 556.00K shares 10-Q · filed 2022-05-06 | ||||||
| 2021-12-31 | 379.00K shares 10-K · filed 2022-03-21 | ||||||
| 2021-09-30 | 379.00K shares 10-Q · filed 2021-11-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |